
## **Corrections & amendments**

## Author Correction: Bridging the gap between innovation and later-stage financing for biotech in Europe

Correction to: *Nature Reviews Drug Discovery* https://doi.org/10.1038/d41573-023-00074-0, published 11 May 2023.

https://doi.org/10.1038/s41573-023-00792-5

Published online: 5 September 2023



Jing Gong, Jean-Loup Romet-Lemonne & Brandy Houser

An error was made in Fig. 1 and in the second paragraph of "Value of venture financing rounds" in the description of the revised set of deals in the corrected version of the article published on 1 June 2023. With the updated inclusion criteria, companies in Europe received -US\$11.2 billion over 483 deals in venture financing rounds in 2021–2022 and companies in the USA received -\$62.5 billion over 1,965 deals. These data show that the average deal size for US-based companies is -1.4 times that of Europe-based companies. Further details have also been added to the supplementary file to clarify the assembly of the dataset and its analysis, including limitations related to the labelling in the database used to assemble the dataset. This has been corrected in the HTML and PDF versions of the article.

© Springer Nature Limited 2023

## Author Correction: Disease modification in inflammatory skin disorders: opportunities and challenges

Correction to: *Nature Reviews Drug Discovery* https://doi.org/10.1038/s41573-023-00735-0, published online 13 July 2023.

https://doi.org/10.1038/s41573-023-00790-7

Published online: 21 August 2023

Check for updates

Thomas Bieber 10

In the version of the article initially published, the name of the drug rezpegaldesleukin was misspelt in Fig. 1, Tables 1 and 2, and the main text. The name of the drug roflumilast was also misspelt in Fig. 1. The errors have been corrected in the HTML and PDF versions of the article.

© Springer Nature Limited 2023